Supernus Pharmaceuticals, Inc. (SUPN) — Stock Score Summary

Supernus Pharmaceuticals, Inc. (SUPN) has a MoatMap StockRank of 72/100 based on Quality (56/100), Value (38/100), and Momentum (60/100) factor scores. The current signal is BUY. Supernus Pharmaceuticals is a mid-cap specialty pharma company facing generic competition and lacking a broad, un-copyable platform moat. It does not align with our high-conviction macro themes.

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for central nervous system (CNS) disorders, including treatments for epilepsy, ADHD, and Parkinson's disease. The company differentiates itself through proprietary drug delivery technologies that enhance therapeutic profiles. It holds a niche position in the complex CNS market, leveraging its specialized development capabilities.

Key Financial Metrics

Price$44.04
Market Cap$2.7B
P/E (Forward)10.29
Price/Book2.42
Return on Equity-2.8%
Return on Invested Capital-4.4%
Debt/Equity3.80
Gross Margin74.1%
Operating Margin-3.6%
Revenue Growth38.6%
Free Cash Flow$133M

Supernus Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Supernus Pharmaceuticals, Inc.’s (SUPN) StockRank?
MoatMap’s StockRank for Supernus Pharmaceuticals, Inc. (SUPN) is 72/100, with a Buy signal. It is a composite of Quality (56), Value (38), and Momentum (60) factor ranks across MoatMap’s 19,000+ stock universe.
Does Supernus Pharmaceuticals, Inc. have an economic moat?
Supernus Pharmaceuticals, Inc. (SUPN) has a Quality factor score of 56/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Supernus Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Supernus Pharmaceuticals, Inc. (SUPN) is Buy, based on a StockRank of 72/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Supernus Pharmaceuticals, Inc. in?
Supernus Pharmaceuticals, Inc. (SUPN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksSUPN deep dive reportAI ChampionsHow we score stocksSense-check another stock